Skip to main content
. 2017 Mar 1;8(15):24753–24761. doi: 10.18632/oncotarget.15800

Figure 4. Pediatric brain tumors were more sensitive to carmofur than temozolomide.

Figure 4

Cell survival studies using MTT assays of various pediatric brain tumors are shown for control cells vs cells treated with 50 μM of carmofur and 100 μM of TMZ. Results are expressed as means and ± s.e.m (N = 3).